Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 125,491 shares of the biopharmaceutical company’s stock after selling 24,628 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.10% of Alnylam Pharmaceuticals worth $29,623,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $1,045,822,000. Geode Capital Management LLC grew its stake in Alnylam Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock valued at $589,209,000 after purchasing an additional 66,928 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 513,962 shares of the biopharmaceutical company’s stock valued at $120,940,000 after purchasing an additional 26,614 shares during the period. Swiss National Bank raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the third quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Eagle Asset Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 25.7% during the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock worth $85,889,000 after purchasing an additional 63,385 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $241.75 on Friday. The company has a market cap of $31.30 billion, a P/E ratio of -111.41 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The company’s 50-day moving average price is $254.86 and its 200-day moving average price is $260.57. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the transaction, the executive vice president now owns 12,881 shares of the company’s stock, valued at $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock valued at $19,958,097 in the last quarter. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ALNY shares. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Chardan Capital reiterated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Sanford C. Bernstein reduced their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. JPMorgan Chase & Co. upped their price target on shares of Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a “neutral” rating in a report on Tuesday. Finally, Morgan Stanley lifted their price objective on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $304.26.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.